Avivi, I.I.AviviCanals, C.C.CanalsVernant, J-PJ-PVernantWulf, GeraldGeraldWulfNagler, A.A.NaglerHermine, O.O.HerminePetersen, E.E.PetersenYakoub-Agha, I.I.Yakoub-AghaCraddock, C.C.CraddockSchattenberg, A.A.SchattenbergNiederwieser, D.D.NiederwieserThomson, K.K.ThomsonBlaise, D.D.BlaiseAttal, M.M.AttalPfreundschuh, MichaelMichaelPfreundschuhPassweg, J.J.PasswegRussell, Nigel H.Nigel H.RussellDreger, PeterPeterDregerSureda, Anna M.Anna M.Sureda2018-11-072018-11-072014https://resolver.sub.uni-goettingen.de/purl?gro-2/33569The objective of this retrospective analysis was to compare outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who received either a matched sibling (sib) or an unrelated donor (URD) allogeneic hematopoietic cell transplantation (allo-HCT). Long-term outcome of 172 DLBCL patients receiving URD-HCT between 2000 and 2007 and reported to the European Group for Blood and Marrow Transplantation, was compared with that of 301 subjects, allografted from sib-HCT. With a median follow-up of 45 months, 3-year PFS approached 35% for both groups; overall survival (OS) was 42% for sib-HCT versus 37% for URD (NS). Multivariate analyses confirmed that donor type was not associated with differences in non-relapse mortality (NRM), relapse rate (RR), PFS or OS. Poor performance status (PS) and refractory disease adversely affected PFS and OS. Prior auto-SCT and multiple previous therapies predicted for shorter PFS. NRM was adversely affected by older age (>= 50 years), poor PS and refractory disease, and RR by time from diagnosis to allo-HCT of < 36 months, prior auto-SCT, refractory disease, poor PS and in vivo T-cell depletion with alemtuzumab. This large study shows for the first time that URD-HCT is not inferior to sib-HCT, providing a reasonable therapeutic approach for DLBCL patients, having no HLA-identical sibling available.journal_article10.1038/bmt.2014.424510071000336037800013